Press Releases

Investors

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead to Report Fiscal 2012 Second Quarter Financial Results
Conference Call Scheduled for Tuesday, May 8, 2012
View HTML
Toggle Summary Arrowhead Research Corporation Acquires Alvos Therapeutics and Proprietary Library of Targeting Peptides
Pioneer in targeting for tumors and tumor vasculature in humans
View HTML
Toggle Summary Arrowhead Releases White Paper on Hepatitis B Virus and Potential RNAi Treatment
Arrowhead Releases White Paper on Hepatitis B Virus and Potential RNAi Treatment PASADENA, Calif. — March 7, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, announced today that it has released a white paper
View HTML
Toggle Summary Arrowhead Research Corporation and Axolabs GmbH Enter into Strategic Alliance and Master Services Agreement for RNAi Therapeutics
Arrowhead Research Corporation and Axolabs GmbH Enter into Strategic Alliance and Master Services Agreement for RNAi Therapeutics PASADENA, Calif. — March 5, 2012 — Arrowhead Research Corporation, a nanomedicine company with development programs in RNAi therapeutics and obesity, and Axolabs GmbH, a
View HTML
Toggle Summary Arrowhead Announces Patent Issuance Covering siRNA Inhibitors of HIF-2α (EPAS1)
Arrowhead Announces Patent Issuance Covering siRNA Inhibitors of HIF-2α (EPAS1) PASADENA, Calif. — February 29, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, announced today that the United States Patent and
View HTML
Toggle Summary Arrowhead Reports Fiscal 2012 First Quarter Financial Results
Arrowhead Reports Fiscal 2012 First Quarter Financial Results PASADENA, Calif. — February 9, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR) , a nanomedicine company with development programs in oncology and obesity, today announced financial results for its fiscal 2012 first quarter ended
View HTML
Toggle Summary Arrowhead to Report Fiscal 2012 First Quarter Financial Results
Conference call Scheduled for Thursday, February 9, 2012
View HTML
Toggle Summary Alnylam and Arrowhead Form Collaboration and Licensing Agreement
– Arrowhead Receives License from Alnylam to Develop RNAi Therapeutic Toward Hepatitis B Virus (HBV) – – Alnylam Gains Access to Arrowhead's Dynamic Polyconjugate (DPC) Delivery Technology for "Alnylam 5x15" Target –
View HTML
Toggle Summary Arrowhead Announces FDA Clearance to Initiate Adipotide™ Phase I Clinical Trial
Arrowhead Announces FDA Clearance to Initiate Adipotide™ Phase I Clinical Trial PASADENA, Calif. — January 4, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology and obesity, today announced that the Investigational New Drug Application
View HTML
Toggle Summary Arrowhead Reports Fiscal 2011 Fourth Quarter and Year-End Financial Results
Arrowhead Reports Fiscal 2011 Fourth Quarter and Year-End Financial Results PASADENA, Calif. — December 20, 2011 — Arrowhead Research Corporation (NASDAQ: ARWRD) , a nanomedicine company with development programs in oncology and obesity, today announced financial results for its fiscal 2011 fourth
View HTML